Cancer clinical trial phases

Key takeaways

• Phase 1 often focuses on safety, dose, and side effects.
• Phase 2 looks more at whether a treatment works for a cancer or setting.
• Phase 3 compares a treatment with standard treatment or another approach.
• Phase alone does not tell you whether a trial is right for you.

Why phases exist

Clinical trials are structured to answer specific questions. A phase helps describe the main purpose and how far along the research is.

Cancer trials can be more complex than a simple phase label. Some modern trials test biomarkers, combinations, or multiple cancer types.

Common phase meanings

• Phase 1: safety, dose, side effects, and how the body handles the treatment.
• Phase 2: whether the treatment has activity against a cancer type or setting.
• Phase 3: comparison against standard treatment or another approach in more people.
• Phase 4: monitoring after approval in broader use.

What a phase does not tell you

A later phase does not automatically mean that a study is better for an individual. It usually means researchers are asking a later-stage question with more prior information. An early-phase trial may be appropriate in some settings, but it often has greater uncertainty about benefit, dose, or side effects.

Some oncology studies combine phases, such as phase 1/2 or phase 2/3. Basket, umbrella, and platform studies may test several tumor types, biomarkers, or treatments under one larger protocol.

Randomization, control groups, and placebos

Many phase 3 trials randomly assign participants to different study groups so the outcomes can be compared fairly. The comparison may be the current standard treatment, another active treatment, or standard care plus an investigational approach.

Placebos are not used to withhold effective treatment when an established therapy is needed. If a placebo is part of a cancer trial, the consent document should explain exactly how it is used and what treatment every group receives.

Participant protections and choices

Before joining, potential participants receive an informed-consent discussion describing the study purpose, procedures, foreseeable risks, possible benefits, alternatives, privacy protections, and whom to contact. Consent is a process, not only a signature.

Participation is voluntary. A participant can ask questions and can leave a study, although the research and oncology teams should explain any safety follow-up or transition in care.

Questions to ask

• What phase is this trial and what is its main question?
• What treatment would I receive outside the trial?
• Is randomization involved?
• What costs, visits, scans, or biopsies are required?
• Can I leave the trial if it is not right for me?

Sources

• NCI: Cancer Clinical Trials Information — NCI guide to understanding cancer clinical trials.
• NCI: How Clinical Trials Work — NCI explanation of eligibility, phases, randomization, and participant protections.